<-- Back to proposed bills
UK-US Arrangement on Pharmaceuticals Pricing and Tariffs
13 April 2026
Type
Written Ministerial Statement
Department
Department for Science, Innovation and Technology
At a Glance
Issue Summary
The UK-US Arrangement on Pharmaceuticals Pricing and Ta [2D [K Tariffs has been published, building on previous economic prosperity deal a [1D [K announcements.
Action Requested
The government is taking steps to improve patient ac [2D [K access to new medicines, clarify US pricing policies, support pharmaceutica [13D [K pharmaceutical exports with tariff-free access, and work towards mutual rec [3D [K recognition of medical device approvals. These actions aim to enhance the l [1D [K life sciences sector's competitiveness and drive economic growth.
Key Facts
- The UK-US Economic Prosperity Deal was announced in May 2 [1D [K 2025.
- NICE cost effectiveness threshold update benefits two medicines fo [2D [K for brain cancer and rare stomach cancer patients.
- Section 232 tariffs o [1D [K of up to 100% on patented pharmaceuticals have been avoided, providing cert [4D [K certainty for UK exporters.
- UK pharmaceutical exports to the US were wor [3D [K worth over £5 billion in 2024.
- The UK pharmaceutical sector added £28.5b [6D [K £28.5bn to the economy and employed over 50,000 people in 2025.
- Section [K 232 and Section 301 tariffs will not be imposed on medical technology expor [5D [K exports for at least three years.
- UCB announced a £500 million investmen [9D [K investment in UK R&D and manufacturing in Surrey.
▸
Assessment & feedback
Summary accuracy